{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T22:08:29Z","timestamp":1722550109591},"reference-count":38,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/etm.2016.3230","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T06:16:45Z","timestamp":1459923405000},"page":"2293-2299","source":"Crossref","is-referenced-by-count":4,"title":["Lamivudine-resistant rtL180M and rtM204I\/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B"],"prefix":"10.3892","volume":"11","author":[{"given":"YANG","family":"WANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHUANG","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YU","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUJUN","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LI","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FENGMIN","family":"LU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHONGPING","family":"DUAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"key20180108123728_b1-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"key20180108123728_b2-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"key20180108123728_b3-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.12392","article-title":"HBeAg-positive chronic hepatitis B: Why do i treat my patients with Nucleos(t)ide analogs?","volume":"1","author":"Buti","year":"2014","journal-title":"Liver Int 34 Suppl"},{"key":"key20180108123728_b4-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/liv.12401","article-title":"HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues?","volume":"1","author":"Vigan\u00f2","year":"2014","journal-title":"Liver Int 34 Suppl"},{"key":"key20180108123728_b5-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"Yuen","year":"2001","journal-title":"Hepatology"},{"key":"key20180108123728_b6-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.26383","article-title":"Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing","volume":"58","author":"Rodriguez","year":"2013","journal-title":"Hepatology"},{"key":"key20180108123728_b7-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"key20180108123728_b8-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"Asian-Pacific consensus update working party on chronic hepatitis B: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"key20180108123728_b9-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"key20180108123728_b10-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key20180108123728_b11-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.80.2.643-653.2006","article-title":"Dynamics of hepatitis B virus resistance to lamivudine","volume":"80","author":"Pallier","year":"2006","journal-title":"J Virol"},{"key":"key20180108123728_b12-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1365-2893.2003.00435.x","article-title":"YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine","volume":"10","author":"Bozdayi","year":"2003","journal-title":"J Viral Hepat"},{"key":"key20180108123728_b13-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1099\/0022-1317-51-8-695","article-title":"Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy","volume":"51","author":"Niesters","year":"2002","journal-title":"J Med Microbiol"},{"key":"key20180108123728_b14-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2893.2005.00687.x","article-title":"Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis","volume":"13","author":"Liaw","year":"2006","journal-title":"J Viral Hepat"},{"key":"key20180108123728_b15-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2012.08.008","article-title":"Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B","volume":"96","author":"Zhao","year":"2012","journal-title":"Antiviral Res"},{"key":"key20180108123728_b16-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1746.2009.05952.x","article-title":"Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study","volume":"25","author":"Vassiliadis","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"key20180108123728_b17-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","article-title":"Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"key20180108123728_b18-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MCG.0000000000000066","article-title":"Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B","volume":"48","author":"Kang","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"key20180108123728_b19-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"key20180108123728_b20-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J Hepatol"},{"key":"key20180108123728_b21-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association: World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"key20180108123728_b22-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12104","article-title":"Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance","volume":"33","author":"Lee","year":"2013","journal-title":"Liver Int"},{"key":"key20180108123728_b23-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Hepatitis B Virus Drug Resistance Working Group: Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"key20180108123728_b24-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/jmv.21206","article-title":"Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy","volume":"80","author":"Ijaz","year":"2008","journal-title":"J Med Virol"},{"key":"key20180108123728_b25-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.3748\/wjg.v18.i44.6437","article-title":"Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment","volume":"18","author":"Ko","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key20180108123728_b26-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/gut.2005.077099","article-title":"Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil","volume":"55","author":"Yeon","year":"2006","journal-title":"Gut"},{"key":"key20180108123728_b27-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/00365521.2012.722671","article-title":"Treatment of lamivudine-resistant chronic hepatitis B infection: A multicenter retrospective study","volume":"48","author":"Lee","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"key20180108123728_b28-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/liv.12036","article-title":"Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): A 2-year follow-up randomized controlled trial","volume":"33","author":"Yim","year":"2013","journal-title":"Liver Int"},{"key":"key20180108123728_b29-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11262-013-1004-1","article-title":"Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: Adefovir monotherapy and adefovir plus lamivudine","volume":"48","author":"Wang","year":"2014","journal-title":"Virus Genes"},{"key":"key20180108123728_b30-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.clinthera.2013.10.002","article-title":"Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: A systematic review and meta-analysis","volume":"35","author":"Huang","year":"2013","journal-title":"Clin Ther"},{"key":"key20180108123728_b31-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1440-1746.2010.06381.x","article-title":"Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy","volume":"25","author":"Kim","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"key20180108123728_b32-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.22634","article-title":"Complex dynamics of hepatitis B virus resistance to adefovir","volume":"49","author":"Pallier","year":"2009","journal-title":"Hepatology"},{"key":"key20180108123728_b33-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"key":"key20180108123728_b34-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-013-0915-1","article-title":"Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy","volume":"47","author":"Deng","year":"2013","journal-title":"Virus Genes"},{"key":"key20180108123728_b35-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3350\/cmh.2013.19.1.29","article-title":"Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B","volume":"19","author":"Park","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"key20180108123728_b36-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1128\/AAC.03845-14","article-title":"Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains","volume":"58","author":"Lee","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key20180108123728_b37-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J Hepatol"},{"key":"key20180108123728_b38-etm-0-0-3230","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2016.3230\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T05:05:07Z","timestamp":1567746307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2016.3230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,6]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/etm.2016.3230"],"URL":"https:\/\/doi.org\/10.3892\/etm.2016.3230","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]}}}